Home > Healthcare > Medical Devices > Diagnostic Devices > Hepatitis Diagnostic Tests Market
Based on product, the hepatitis diagnostic tests market is segmented as reagents & kits and instruments. The reagents & kits held a majority market value of USD 2.3 billion in 2022. This high business share is owing to several benefits offered by reagents & kits in precise and accurate screening of hepatitis disease. Reagents and kits are designed for highly specific and sensitive screening of hepatitis B and C virus and can accurately detect the low level of components in a sample particularly during the early stages of infection. These products can provide faster results that allows for prompt diagnosis and treatment, thereby preventing disease progression.
Additionally, raising number of blood donations has resulted in demand for faster clinical outcomes and these reagents and kits are designed to perform high volume diagnostic test and are ideal for large-scale screening programs. Therefore, due to several benefits offered by reagents & kits is expected to propel the market development.
Based on technology the hepatitis diagnostic tests market is segmented as enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDTs), polymerase chain reaction (PCR), isothermal nucleic acid amplification test (INAAT) and others. The enzyme-linked immunosorbent assay held a dominant market share in 2022 and is anticipated to grow at a lucrative pace by 2032.
Enzyme-linked immunosorbent assay (ELISA) is intended for the diagnostic test for hepatitis, particularly for hepatitis B and C. This technology uses antibodies to detect the presence of viral antigens or antibodies in a patient's blood or serum. ELISA is a highly sensitive and specific test for the detection of hepatitis virus infections. It can be used for both screening and confirmatory testing to provide a comprehensive diagnostic evaluation. Therefore, owing to several advantages offered by ELISA is estimated to increase the product acceptance rate in several countries worldwide.
Based on test type the hepatitis diagnostic tests market is segmented as blood tests, imaging test and liver biopsy. Blood tests is further segmented as liver function tests, immunoassays and nucleic acid tests. The blood tests segment held a major revenue share with over 45% in 2022. This majority market share is driven by several clinical benefits offered by blood tests in the diagnosis and treatment of hepatitis, thereby preventing chronic ailments. Blood tests can detect the presence of symptomatic hepatitis virus and accurately differentiate between different types of hepatitis viruses.
Additionally, tests help to identify infected individuals and measure the effectiveness of antiviral therapy and track disease progression over time. Therefore, blood tests for hepatitis screening are an essential tool for the early detection and diagnosis of hepatitis virus infections. They are highly accurate, non-invasive, and can be used for monitoring treatment and preventing transmission. Thus, the high-quality blood tests and growing number of blood donations are anticipated to expedite the business growth.
Based on end-use the hepatitis diagnostic tests market is segmented as hospitals, diagnostic laboratories, and others. Hospitals segment held 35% business share in 2022 and is projected to grow at a rapid pace by 2032. This is attributable to the increased usage of hepatitis diagnostic tests in hospital settings, that is foreseen to increase patients' choice for hospitals by providing better results. Growing admissions with target disorders comprising chronic diseases and surging disease screening initiatives coupled with the accessibility of highly skilled healthcare professionals are some other attributes that are propelling the industry landscape.
Additionally, the high chronic disease incidence in developed countries with robust healthcare infrastructure is projected to positively impact segment expansion. Surging hepatitis B and C cases, liver cirrhosis and other disorder prevalence will significantly propel the diagnostic test rate at hospitals. Thus, accessibility to better treatment & diagnosis coupled with the rising prevalence of hepatitis and associated conditions is estimated to boost patient visits to hospitals.
North American hepatitis diagnostic tests market crossed USD 1.4 billion in 2022. This majority market share is attributable to several factors such as the growing prevalence of hepatitis and related chronic diseases, rising healthcare expenditure along with growing product adoption across the country. The adoption of cutting-edge technologies is facilitated by the involvement of major stakeholders, that helps in the region's industrial development. The high prevalence of hepatitis C and the rising hospital admission in the region emphasize the growing need for blood transfusion in related procedures.
Furthermore, approximately 17,000 new Hepatitis C cases are estimated to witness each year in the U.S. Moreover, the availability of advanced technologies that enhance the quality of hepatitis diagnostic tests foster the development of the regional market.